Chiesi announced today that it appointed former Baxter and Medtronic executive Giuseppe Accogli as its new group CEO. Parma, Italy–based Chiesi said Accogli’s appointment becomes effective April 3, 2023. The R&D-focused pharmaceutical company develops and commercializes products for the hospital, rare disease and adjacent specialty care settings. Accogli brings 25 years of international experience to…
Cardinal Health, Palantir partner on AI for pharmaceutical products
Cardinal Health (NYSE:CAH) announced that it entered into a strategic collaboration with Palantir Technologies (NYSE:PLTR). The partnership pairs the companies to design a solution to give health systems and hospitals dynamic purchase decision insights. These insights help them quickly improve their bottom line. Dublin, Ohio-based Cardinal Health plans to integrate this solution into Foundry, Palantir’s…
Eli Lilly to invest $450M in North Carolina diabetes treatment manufacturing facility
Eli Lilly (NYSE:LLY) announced today that it plans to invest an additional $450 million at a North Carolina manufacturing facility. Lilly expects the investment to create at least 100 new jobs at the Research Triangle Park, North Carolina, plant. Its expansion includes additional parenteral filling, device assembly and packaging capacity. Indianapolis-based Lilly said this expansion supports…
Baxter may look to sell off BioPharma business
Baxter (NYSE:BAX) today unveiled a strategic roadmap for its future that includes potential plans for its BioPharma Solutions (BPS) business. The company’s plans include a simplified commercial and manufacturing footprint, according to a news release. The company also intends to improve its capital structure. That includes a review of strategic alternatives for its BioPharma Solutions…
Healiva buys critical cell therapy manufacturing assets from B. Braun
Healiva announced today that it acquired critical manufacturing assets from B. Braun’s B. Braun Medical AG Switzerland affiliate. The companies declined to disclose financial details for the acquisition. Lugano, Switzerland-based Healiva develops precision medicine for patients with chronic and acute wounds. It acquired a qualified cell bank for the manufacturing of its first cell therapy…
Pfizer beats The Street in Q3, raises guidance
Pfizer (NYSE:PFE) shares ticked up before hours on third-quarter results that topped the consensus forecast. Shares of PFE ticked up 3.7% at $48.29 apiece before the market opened today. The New York-based pharmaceutical giant posted profits of $8.6 billion. That amounts to $1.51 per share on sales of $22.6 billion for the three months ended…
Lilly establishing pharmaceutical manufacturing scholarship program at Purdue
Eli Lilly (NYSE:LLY) announced yesterday that it committed $92.5 million to establish a scholarship program at Purdue University. The funding establishes an innovative new pharmaceutical manufacturing scholarship program. Lilly and Purdue also renewed their strategic research collaboration. This involves a series of moves aimed at expanding their impact in Indiana and improving lives around the…
Aphena Pharma Solutions completes $20M expansion in Tennessee
Aphena Pharma Solutions announced that it completed its $20 million expansion and renovation in Cookeville, Tennessee. The company began its expansion and renovation in mid-2019. It said in a news release that it adds a “large amount” of solid dose packaging capacity. “The expansion added a new 500,000-square-foot facility that is purpose-built for FDA pharmaceutical…
Johnson & Johnson beats The Street in Q3, Pharma sales rise
Johnson & Johnson (NYSE:JNJ) today reported third-quarter results that topped the consensus forecast, with international pharma sales up 2.6% or 9.0% operationally. Drugs fueling growth include Stelara (ustekinumab), Darzalex (daratumumab), Tremfya (guselkumab), Xarelto (rivaroxaban) and Erleada (apalutamide). J&J licensed Darzelex from Genmab. The drug won FDA approval in 2015 for patients with previously treated multiple myeloma. Darzalex…
Thermo Fisher Scientific launches cell therapy manufacturing tech
Thermo Fisher Scientific (NYSE:TMO) announced today that it unveiled the Gibco CTS DynaCellect magnetic separation system. Waltham, Massachusetts-based Thermo Fisher designed DynaCellect to help cell therapy developers easily move from process and clinical development to commercial manufacturing. The next-generation instrument features cell isolation, activation and depletion along with Dynabeads magnetic beads removal. Thermo Fisher said…